NcXHF

MOY ET AL
References
1. Bekelman JE, Li Y, Gross CP. Scope and impact of fınancial conflicts of
interest in biomedical research: a systematic review. JAMA. 2003;289:
454-465.
2. Hampson LA, Joffe S, Fowler R, et al. Frequency, type, and monetary
value of fınancial conflicts of interest in cancer clinical research. J Clin
Oncol. 2007;25:3609-3614.
3. Peppercorn J, Blood E, Winer E, et al. Association between pharmaceutical
involvement and outcomes in breast cancer clinical trials. Cancer.
2007;109:1239-1246.
4. Riechelmann RP, Wang L, O’Carroll A, et al. Disclosure of conflicts of
interest by authors of clinical trials and editorials in oncology. J Clin
Oncol. 2007;25:4642-4647.
5. Moy B, Bradbury AR, Helft PR, et al. Correlation between fınancial relationships
with commercial interests and research prominence at an
oncology meeting. J Clin Oncol. 2013;31:2678-2684.
6. Campbell EG, Moy B, Feibelmann S, et al. Institutional academic industry
relationship: results of interviews with university leaders. Account
Res. 2004;11:103-118.
7. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic
industry relationships. JAMA. 2007;298:1779-1786.
8. Lo B. Serving two masters-conflicts of interest in academic medicine.
N Engl J Med. 362:669-671.
9. Cho MK, Shohara R, Schissel A, et al. Policies on faculty conflicts of
interest at US universities. JAMA. 2000;284:2203-2208.
10. Moy B. Medical integrity up in smoke? Conflicts of interest and the lung
cancer screening controversy. Oncologist. 2008;13:474-476.
11. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in
clinical research: Issues for clinical investigators. Acad Med. 2003;78:
769-774.
12. Lipton S, Boyd EA, Bero LA. Conflicts of interest in academic research:
policies, processes, and attitudes. Account Res. 2004;11:83-102.
13. Lexchin J, Sekeres M, Gold J, et al. National evaluation of policies on
individual fınancial conflicts of interest in Canadian academic health
science centers. J Gen Intern Med. 2008;23:1896-1903.
14. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that
create conflicts of interest: a policy proposal for academic medical centers.
JAMA. 2006;295:429-433.
15. Centers for Medicare & Medicaid Services. Natures of Payment.
www.cms.gov/OpenPayments/About/Natures-of-Payment.html. Accessed
February 14, 2015.
16. Ratain MJ. Forecasting unanticipated consequences of “The Sunshine
Act”: mostly cloudy. J Clin Oncol. 2014;32:2293-2295.
17. International Society for Medical Publication Professionals. ISMPP
Sunshine Act Information Update. http://www.ismpp.org/assets/docs/
Inititives/Sunshine_Act/sunshine%20act%20interpretation%20update_
february%202014_fınal.pdf. Accessed January 8, 2015.
18. Gray SW, Hlubocky FJ, Ratain MJ, et al. Attitudes toward research participation
and investigator conflicts of interest among advanced cancer
patients participating in early phase clinical trials. J Clin Oncol. 2007;25:
3488-3494.
19. Korownyk C, Kolber MR, McCormack J, et al. Televised medical talk
shows-what they recommend and the evidence to support their recommendations:
a prospective observational study. BMJ. 2014;g7346.
20. Biegler P, Vargas P. Ban the sunset? Nonpropositional content and regulation
of pharmaceutical advertising. Am J Bioeth. 2013;13:3-13.
21. Citizen.org. Title XX. http://www.citizen.org/Page.aspx?pid3246.
Accessed February 25, 2015.
22. Every-Palmer S, Duggal R, Menkes DB. Direct-to-consumer advertising
of prescription medication in New Zealand. N Z Med J. 2014;127:102-
110.
23. Schwartz MI. To ban or not to ban-that is the question: the constitutionality
of a moratorium on consumer drug advertising. Food Drug Law J.
2008;63:1-33.
24. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a fınancial
toxicity patient-reported outcome in cancer: the COST measure.
Cancer. 2014;120:3245-3253.
25. Ceccoli SJ, Klotz RJ. Taking your medicine? Attitudes toward direct-toconsumer
advertising (DTCA). The Social Science Journal. 2013;50:501-
509.
26. United States Department of Health and Human Services, Food and
Drug Administration. Draft guidance for industry: Consumer-directed
broadcast advertisements. Federal Register. 1997;62:43171-43173.
27. Department of Health and Human Services and US Food and Drug Administration.
Guidance For Industry on Consumer-Directed Broadcast
Advertisements; Availability. Federal Register. 1999;64:43197-43198.
28. Liu Q, Gupta S. Direct-to-consumer-advertising of pharmaceuticals: An
integrative review. In Ding M, Eliashberg J, Stremersch S (eds). Innovation
and Marketing in the Pharmaceutical Industry: Emerging Practices,
Research, and Policies. New York: Springer, 2013;629-650.
29. Aikin KJ, Swasy JL, Braman AC. Patient and Physician Attitudes and
Behaviors Associated with DTC Promotion of Prescription Drugs —
Summary of FDA Survey Research Results. US Department of Health
and Human Services, US Food and Drug Administration, Center for
DrugEvaluationandResearch.November19,2004.http://www.fda.gov/
downloads/Drugs/ScienceResearch/ResearchAreas/DrugMarketing
AdvertisingandCommunicationsResearch/UCM152860.pdf. Accessed
on January 12, 2015.
30. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests
for direct-to-consumer advertised antidepressants: a randomized
controlled trial. JAMA. 2005;293:1995-2002.
31. Ukens C. Consumer advertising found to pack prescribing punch. Drug
Topics. 1992;136:24-26.
32. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientifıc
drug prescribing. Soc Sci Med. 1989;28:577-582.
33. Gilbody S, Wilson P, Watt I. Benefıts and harms of direct to consumer
advertising: a systematic review. Qual Saf Health Care. 2005;14:246-250.
34. Lipsky MS, Taylor CA. The opinions and experiences of family physicians
regarding direct-to-consumer advertising. J Fam Pract. 1997;45:
495-499.
35. Brodie M, Levitt L. Drug advertising: the right or wrong prescription for
our ailments? Nat Rev Drug Discov. 2002;1:916-920.
36. Abel GA, Penson RT, Joffe S, et al. Direct-to-consumer advertising in
oncology. Oncologist. 2006;11:217-226.
37. Abel GA, Burstein HJ, Hevelone ND, et al. Cancer-related direct-toconsumer
advertising: awareness, perceptions, and reported impact
among patients undergoing active cancer treatment. J Clin Oncol. 2009;
27:4182-4187.
38. Viale PH, Sanchez Yamamoto D. The attitudes and beliefs of oncology
nurse practitioners regarding direct-to-consumer advertising of prescription
medications. Oncol Nurs Forum. 2004;31:777-783.
39. Illes J, Kann D, Karetsky K, et al. Advertising, patient decision making,
and self-referral for computed tomographic and magnetic resonance
imaging. Arch Intern Med. 2004;164:2415-2419.
40. Kontos EZ, Viswanath K. Cancer-related direct-to-consumer advertising:
a critical review. Nat Rev Cancer. 2011;11:142-150.
41. Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology
screening tests. N Engl J Med. 2002;346:529-531.
136 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook